Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PhaseRx, Inc. (PZRXQ : OTC)

• Company Description    PhaseRx, Inc. is a preclinical biopharmaceutical company. It is engaged in developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The Company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology(TM) platform. PhaseRx, Inc. is headquartered in Seattle, Wash. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.00 Daily Weekly Monthly 20 Day Moving Average: shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: -0.60 52 Week High: $0.00 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week % % 12 Week % % Year To Date % %

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 410 W. Harrison Street Suite 300 - Seattle,WA 98119 USA ph: 206-805-6300 fax: - robert.uhl@westwicke.com http://www.phaserx.com

• General Corporate Information    Officers Steven Gillis - Chairman Robert W. Overell - Chief Executive Officer; President Shing-Yin (Helen) Tsui - Senior Vice President; Finance and Secretary Peggy V. Phillips - Director Brian G. Atwood - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 71723F103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: -0.60 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - - 12/31/22 - - 09/30/22 - - ROA 03/31/23 - - 12/31/22 - - 09/30/22 - - Current Ratio 03/31/23 - - 12/31/22 - - 09/30/22 - - Quick Ratio 03/31/23 - - 12/31/22 - - 09/30/22 - - Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - - 12/31/22 - - 09/30/22 - - Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Capital 03/31/23 - - 12/31/22 - - 09/30/22 - -

Powered by Zacks Investment Research ©